Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Organon’s Asenapine Shows Less Weight Gain Than Zyprexa In Phase III Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Patients taking asenapine had approximately two-fold lower incidence of clinically significant weight gain; efficacy profile was similar to Lilly’s olanzapine.

You may also be interested in...



FDA Accepts NDA For Schering-Plough Antipsychotic Asenapine

Schering’s acquisition of asenapine developer Organon was completed Nov. 19; Dutch firm has previously reported positive data in comparison to J&J’s Risperdal and Lilly’s Zyprexa.

FDA Accepts NDA For Schering-Plough Antipsychotic Asenapine

Schering’s acquisition of asenapine developer Organon was completed Nov. 19; Dutch firm has previously reported positive data in comparison to J&J’s Risperdal and Lilly’s Zyprexa.

Organon Asenapine Study Shows Improved Effect On Negative Schizophrenia Symptoms Over Risperdal

Patients treated with asenapine also experienced less weight gain and lower levels of prolactin, a signal associated with improved sexual side effects.

Related Content

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel